Natarajan Sethuraman Sells 1,409 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 1,409 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $20.01, for a total value of $28,194.09. Following the completion of the transaction, the insider now owns 163,588 shares of the company’s stock, valued at $3,273,395.88. This represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Natarajan Sethuraman also recently made the following trade(s):

• On Wednesday, November 13th, Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock. The stock was sold at an average price of $20.04, for a total transaction of $54,108.00.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total value of $9,144.00.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $19.04 on Friday. Entrada Therapeutics, Inc. has a 1-year low of $10.75 and a 1-year high of $20.49. The firm has a market capitalization of $712.48 million, a P/E ratio of 11.97 and a beta of -0.26. The company’s 50-day moving average is $16.62 and its 200 day moving average is $15.85.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The firm had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million. Research analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TRDA shares. HC Wainwright raised their price target on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Oppenheimer boosted their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th.

Institutional Investors Weigh In On Entrada Therapeutics

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new stake in shares of Entrada Therapeutics during the second quarter worth $636,000. The Manufacturers Life Insurance Company increased its stake in Entrada Therapeutics by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after purchasing an additional 2,146 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Entrada Therapeutics during the 1st quarter worth approximately $79,000. Vanguard Group Inc. lifted its holdings in Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after purchasing an additional 13,742 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after purchasing an additional 11,965 shares during the period. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.